Page 90 - Read Online

Page 6 of 11 Yaroustovsky et al. Vessel Plus 2019;3:9 I http://dx.doi.org/10.20517/2574-1209.2019.02

Table 3. Changes of laboratory data in the H.E.L.P.-apheresis group
Indices Before procedures After procedures P value
Lp(a), mg/dL 151.5 (80.8-185) 47.6 (33-68.6) 0.001
Total cholesterol, mmol/L 5.0 (4.6-5.5) 2.38 (2.2-2.7) 0.001
Triglyceride, mmol/L 1.5 (1.1-1.9) 0.9 (0.5-1.2) 0.001
LDL, mmol/L 2.9 (2.6-3.2) 1.0 (0.9-1.3) 0.001
HDL, mmol/L 1.28 (1.0-1.5) 0.91 (0.7-1.1) 0.001
Atherogenic index 2.9 (2.3-4.2) 1.8 (1.3-2.8) 0.001
ApoA, mg/dL 142 (116-151) 93 (78-114) 0.001
ApoB100, mg/dL 89 (81-99) 41 (32-49) 0.001
Index ApoB100/ApoA 0.7 (0.6-0.8) 0.47 (0.3-0.6) 0.001
C-RP, mg/dL 0.13 (0.9-0.3) 0.06 (0.04-0.4) 0.001
Total protein, g/L 66 (62-69) 50 (46-53) 0.001
Albumin, g/L 41 (39-43) 32 (29-34) 0.001

LDL: low density lipoprotein; HDL: high density lipoprotein; C-RP: C-reactive protein

Table 4. Changes of laboratory data in the lipid-filtration group
Indices Before procedures After procedures P value
Lp(a), mg/dL 124 (93-169) 42.7 (32.4-54.2) 0.001
Total cholesterol, mmol/L 5.7 (4.5-7.4) 1.9 (1.7-2.8) 0.001
Triglyceride, mmol/L 2.2 (1.7-2.6) 0.7 (0.5-0.8) 0.001
LDL, mmol/L 3.8 (2.5-5.7) 1.2 (0.8-2.1) 0.001
HDL, mmol/L 0.9 (0.9-1.0) 0.7 (0.6-0.8) 0.001
Atherogenic index 4.5 (3.8-6.9) 2.1 (1.5-3.5) 0.001
ApoA, mg/dL 119 (105-140) 95 (83-107) 0.001
ApoB100, mg/dL 111.5 (97.75-147.75) 33 (21.75-53) 0.001
Index ApoB100/ApoA 0.8 (0.75-1.28) 0.34 (0.2-0.65) 0.001
C-RP, mg/dL 0.1 (0.7-0.18) 0.06 (0.04-0.1) 0.001
Total protein, g/L 70 (67-72) 55 (52-57) 0.001
Albumin, g/L 43 (42-46) 37 (35-38) 0.001

LDL: low density lipoprotein; HDL: high density lipoprotein; C-RP: C-reactive protein

filtration. However, these changes were within the physiological intervals and didn’t influence the clinical
state of patients.

DISCUSSION
Our study presented 2 techniques of selective lipid apheresis for corrected lipid metabolism disorders in
the high-risk patients with cardiovascular diseases. This group of patients needed more aggressive lipid-
lowering therapy with selective methods of lipid apheresis as the conventional therapy was insufficient and
the level of Lp(a) was high. In this regard, we adhered to the clinical guidelines of MH of RF for treatment
of Familial hypercholesterolemia, to the recommendations of associations for atherosclerosis treatment
and recommendations of apheresis societies [1,31-34] . According to them, the program lipid apheresis is
recommended for the patients with cardiovascular diseases due to atherosclerosis with hypercholesterolemia
combined with high levels of Lp(a) (more than 60 mg/dL).

Lipid apheresis therapies (regardless of the type of technique) are mainly aimed at dyslipidemia correction,
atherogenic lipids elimination with preservation in antiatherogenic fractions circulation.

The decrease of lipid levels [LDL, Lp(a)] was statistically significant in both groups, and our results
correlate with other studies. According to a number of other trials, decrease of atherogenic lipoproteins
levels during the treatment is approximately within 60%-80% [35,36] . Selective elimination of a great amount
of lipid substances modifies the ratio of their fractions expectedly during the treatment. Although we